Peringatan Keamanan

Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.

Diethylstilbestrol

DB00255

small molecule approved investigational withdrawn

Deskripsi

A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)

The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.L43942

Struktur Molekul 2D

Berat 268.356
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1322 Data
Reserpine Reserpine may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Progesterone Progesterone may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Chlorpromazine Chlorpromazine may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Cholic Acid Cholic Acid may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Fusidic acid Fusidic acid may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Letermovir The metabolism of Diethylstilbestrol can be decreased when combined with Letermovir.
Valinomycin Valinomycin may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Erythromycin The serum concentration of Diethylstilbestrol can be increased when it is combined with Erythromycin.
Olmesartan Olmesartan may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Diethylstilbestrol.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Diethylstilbestrol.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Diethylstilbestrol.
Colchicine The metabolism of Colchicine can be decreased when combined with Diethylstilbestrol.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Diethylstilbestrol.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Diethylstilbestrol.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Diethylstilbestrol.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Diethylstilbestrol.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Diethylstilbestrol.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Diethylstilbestrol.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Diethylstilbestrol.
Aprepitant The serum concentration of Diethylstilbestrol can be decreased when it is combined with Aprepitant.
Exenatide Exenatide can cause a decrease in the absorption of Diethylstilbestrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thalidomide Diethylstilbestrol may increase the thrombogenic activities of Thalidomide.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Diethylstilbestrol.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Diethylstilbestrol.
Mifepristone The serum concentration of Diethylstilbestrol can be increased when it is combined with Mifepristone.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Diethylstilbestrol.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Diethylstilbestrol.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Diethylstilbestrol.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Diethylstilbestrol.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Diethylstilbestrol.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Diethylstilbestrol.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Diethylstilbestrol.
Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Diethylstilbestrol.
Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Diethylstilbestrol.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diethylstilbestrol.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Diethylstilbestrol.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.
Lenalidomide Diethylstilbestrol may increase the thrombogenic activities of Lenalidomide.
Ospemifene The risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Ospemifene.
Ropinirole Diethylstilbestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Diethylstilbestrol.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Diethylstilbestrol.
Cetuximab Diethylstilbestrol may increase the thrombogenic activities of Cetuximab.
Human immunoglobulin G Diethylstilbestrol may increase the thrombogenic activities of Human immunoglobulin G.
Omalizumab Diethylstilbestrol may increase the thrombogenic activities of Omalizumab.
Gemtuzumab ozogamicin Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide Diethylstilbestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Trastuzumab Diethylstilbestrol may increase the thrombogenic activities of Trastuzumab.
Rituximab Diethylstilbestrol may increase the thrombogenic activities of Rituximab.
Basiliximab Diethylstilbestrol may increase the thrombogenic activities of Basiliximab.
Muromonab Diethylstilbestrol may increase the thrombogenic activities of Muromonab.
Digoxin Immune Fab (Ovine) Diethylstilbestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Tositumomab Diethylstilbestrol may increase the thrombogenic activities of Tositumomab.
Alemtuzumab Diethylstilbestrol may increase the thrombogenic activities of Alemtuzumab.
Efalizumab Diethylstilbestrol may increase the thrombogenic activities of Efalizumab.
Antithymocyte immunoglobulin (rabbit) Diethylstilbestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Natalizumab Diethylstilbestrol may increase the thrombogenic activities of Natalizumab.
Palivizumab Diethylstilbestrol may increase the thrombogenic activities of Palivizumab.
Daclizumab Diethylstilbestrol may increase the thrombogenic activities of Daclizumab.
Bevacizumab Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.
Technetium Tc-99m arcitumomab Diethylstilbestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Eculizumab Diethylstilbestrol may increase the thrombogenic activities of Eculizumab.
Panitumumab Diethylstilbestrol may increase the thrombogenic activities of Panitumumab.
Ranibizumab Diethylstilbestrol may increase the thrombogenic activities of Ranibizumab.
Galiximab Diethylstilbestrol may increase the thrombogenic activities of Galiximab.
Pexelizumab Diethylstilbestrol may increase the thrombogenic activities of Pexelizumab.
Epratuzumab Diethylstilbestrol may increase the thrombogenic activities of Epratuzumab.
Bectumomab Diethylstilbestrol may increase the thrombogenic activities of Bectumomab.
Oregovomab Diethylstilbestrol may increase the thrombogenic activities of Oregovomab.
IGN311 Diethylstilbestrol may increase the thrombogenic activities of IGN311.
Adecatumumab Diethylstilbestrol may increase the thrombogenic activities of Adecatumumab.
Labetuzumab Diethylstilbestrol may increase the thrombogenic activities of Labetuzumab.
Matuzumab Diethylstilbestrol may increase the thrombogenic activities of Matuzumab.
Fontolizumab Diethylstilbestrol may increase the thrombogenic activities of Fontolizumab.
Bavituximab Diethylstilbestrol may increase the thrombogenic activities of Bavituximab.
CR002 Diethylstilbestrol may increase the thrombogenic activities of CR002.
Rozrolimupab Diethylstilbestrol may increase the thrombogenic activities of Rozrolimupab.
Girentuximab Diethylstilbestrol may increase the thrombogenic activities of Girentuximab.
Obiltoxaximab Diethylstilbestrol may increase the thrombogenic activities of Obiltoxaximab.
XTL-001 Diethylstilbestrol may increase the thrombogenic activities of XTL-001.
NAV 1800 Diethylstilbestrol may increase the thrombogenic activities of NAV 1800.
Briakinumab Diethylstilbestrol may increase the thrombogenic activities of Briakinumab.
Otelixizumab Diethylstilbestrol may increase the thrombogenic activities of Otelixizumab.
AMG 108 Diethylstilbestrol may increase the thrombogenic activities of AMG 108.
Iratumumab Diethylstilbestrol may increase the thrombogenic activities of Iratumumab.
Enokizumab Diethylstilbestrol may increase the thrombogenic activities of Enokizumab.
Ramucirumab Diethylstilbestrol may increase the thrombogenic activities of Ramucirumab.
Farletuzumab Diethylstilbestrol may increase the thrombogenic activities of Farletuzumab.
Veltuzumab Diethylstilbestrol may increase the thrombogenic activities of Veltuzumab.
Ustekinumab Diethylstilbestrol may increase the thrombogenic activities of Ustekinumab.
PRO-542 Diethylstilbestrol may increase the thrombogenic activities of PRO-542.
TNX-901 Diethylstilbestrol may increase the thrombogenic activities of TNX-901.

Target Protein

Estrogen receptor beta ESR2
Estrogen receptor ESR1
Estrogen-related receptor gamma ESRRG
Steroid hormone receptor ERR1 ESRRA
Steroid hormone receptor ERR2 ESRRB
Nuclear receptor coactivator 2 NCOA2
Nuclear receptor subfamily 1 group I member 2 NR1I2
Androgen receptor AR
Sex hormone-binding globulin SHBG

Referensi & Sumber

Synthesis reference: Adler, E.,Gie, G.J. and von Euler, H.; US. Patent 2,421,401; June 3, 1947; assigned to Hoffmann-La Roche, Inc.
Artikel (PubMed)
  • PMID: 6436700
    Authors unspecified: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984 Nov 15;311(20):1281-6.
  • PMID: 13104505
    DIECKMANN WJ, DAVIS ME, RYNKIEWICZ LM, POTTINGER RE: Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol. 1953 Nov;66(5):1062-81.
  • PMID: 7001242
    Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21.
  • PMID: 5171004
    Kuchera LK: Postcoital contraception with diethylstilbestrol. JAMA. 1971 Oct 25;218(4):562-3.
  • PMID: 5549830
    Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878-81.

Contoh Produk & Brand

Produk: 10 • International brands: 3
Produk
  • Honvol Ampoules 250mg
    Liquid • 250 mg / 5 mL • Intravenous • Canada • Approved
  • Honvol Tablets 100mg
    Tablet • 100 mg / tab • Oral • Canada • Approved
  • Stilbestrol 0.5mg Tablet
    Tablet • .5 mg / tab • Oral • Canada • Approved
  • Stilbestrol 1.0mg Tablet
    Tablet • 1 mg / tab • Oral • Canada • Approved
  • Stilbestrol Tab 1mg
    Tablet • 1 mg / tab • Oral • Canada • Approved
  • Stilbestrol Tablets 0.1 mg
    Tablet • 0.105 mg • Oral • Canada • Approved
  • Stilbestrol Tablets 0.5 mg
    Tablet • 0.51 mg • Oral • Canada • Approved
  • Stilbestrol Tablets 1.0 mg
    Tablet • 1.0 mg • Oral • Canada • Approved
Menampilkan 8 dari 10 produk.
International Brands
  • Distilbene — Gerda
  • Stilbestrol — Nysco
  • Stilbetin — Bristol Myers-Squibb

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul